362703-34-2

Basic information

• Product Name: 1-tert-butyl4-Methyl4-cyanopiperidine-1,4-dicarboxylate
• Synonyms: 1-tert-butyl4-Methyl4-cyanopiperidine-1,4-dicarboxylate;Methyl 4-cyanopiperidine-4-carboxylate hydrochloride;1,4-Piperidinedicarboxylic acid, 4-cyano-, 1-(1,1-dimethylethyl) 4-methyl ester
• CAS NO: 362703-34-2
• Molecular Formula: C₁₃H₂₀N₂O₄
• Molecular Weight: 269.31684
• Mol File: 362703-34-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-tert-butyl4-Methyl4-cyanopiperidine-1,4-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-tert-butyl4-Methyl4-cyanopiperidine-1,4-dicarboxylate(362703-34-2)
• EPA Substance Registry System: 1-tert-butyl4-Methyl4-cyanopiperidine-1,4-dicarboxylate(362703-34-2)

Safety Data

• Hazardous Substances Data: 362703-34-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
1-tert-butyl-4-methyl-4-cyanopiperidine-1,4-dicarboxylate is used as a building block for the synthesis of various pharmaceutical and medicinal products. Its unique structure allows for the creation of diverse drug candidates with potential therapeutic applications.
Used in Drug Development Research:
In the field of drug development, 1-tert-butyl-4-methyl-4-cyanopiperidine-1,4-dicarboxylate serves as a key intermediate in the synthesis of novel compounds with potential biological activities. Its presence in the molecular structure can influence the pharmacokinetics, pharmacodynamics, and overall efficacy of the resulting drugs.
Used in Medicinal Chemistry:
1-tert-butyl-4-methyl-4-cyanopiperidine-1,4-dicarboxylate is utilized in medicinal chemistry for the design and optimization of drug molecules. Its functional groups can be modified or used to attach other chemical moieties, enabling the development of compounds with improved potency, selectivity, and safety profiles.
Used in Organic Synthesis:
Beyond its applications in the pharmaceutical industry, 1-tert-butyl-4-methyl-4-cyanopiperidine-1,4-dicarboxylate can also be employed in organic synthesis for the preparation of other organic compounds with various applications in different industries, such as materials science, agrochemicals, and specialty chemicals.

Upstream product

• 105-34-0 methyl 2-cyanoacetate 
• 159635-50-4 Bis-(2-bromo-ethyl)-carbamic acid tert-butyl ester 
• 362703-33-1 C₁₆H₁₈N₂O₄ 
• 24424-99-5 di-tert-butyl dicarbonate 
• 4395-98-6 4-cyanopiperidine 
• 1016258-66-4 1-(tert-butyl) 4-ethyl 4-cyanopiperidine-1,4-dicarboxylate 
• 124-41-4 sodium methylate 
• 91419-52-2 1-tert-butoxycarbonyl-4-cyanopiperidine 

Downstream Products

• 1338251-67-4 C₁₇H₂₄N₂O₅*ClH 
• 1338251-68-5 C₁₅H₁₈Cl₂N₂O₃*ClH 
• 1338251-86-7 C₂₅H₃₂N₂O₆ 
• 1338251-87-8 C₂₅H₃₂N₂O₆ 
• 1338251-88-9 C₂₅H₃₂N₂O₆ 
• 1338251-89-0 C₂₅H₂₉F₃N₂O₅ 
• 1338251-90-3 C₂₅H₂₉F₃N₂O₅ 
• 1338251-91-4 C₂₅H₂₉F₃N₂O₅ 
• 1338251-92-5 C₂₉H₃₆N₂O₆ 
• 1338251-93-6 C₂₅H₃₂N₂O₅ 
• 1338251-94-7 C₂₃H₂₆Cl₂N₂O₄ 
• 1338251-95-8 C₂₃H₂₆Cl₂N₂O₄ 
• 1338251-96-9 C₂₃H₂₆Cl₂N₂O₄ 
• 1338251-97-0 C₂₃H₂₃Cl₂F₃N₂O₃ 

Relevant articles and documents

LIM KINASE INHIBITORS

The present invention relates to new kinase inhibitors, more specifically LIM Kinase inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and Prophylaxis of disease. In particular, the present invention relates to new LIMK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and Prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said Compounds in the manufacture of a medicament for the application to a number of therapeutic indications including Ophthalmic and intestinal diseases.

Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers

To obtain selective and potent inhibitor for T-type calcium channel by ligand based drug design, 4-piperidinecarboxylate and 4-piperidinecyanide derivatives were prepared and evaluated for in vitro and in vivo activity against α1G calcium channel. Among them, several compounds showed good T-type calcium channel inhibitory activity and minimal off-target activity over hERG channel (% inhibition at 10 μM = 61.85-71.99, hERG channel IC50 = 1.57 ± 0.14-4.98 ± 0.36 μM). Selected compound 31a was evaluated on SNL model of neuropathic pain and showed inhibitory effect on mechanical allodynia.

Synthesis and structure-activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors

A novel series of achiral TNF-α converting enzyme (TACE) inhibitors has been discovered. These compounds exhibited activities from 0.35 to 11 nM in a porcine TACE assay and inhibited TNF-α production in an LPS-stimulated whole blood assay with an IC5

Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha

The present application describes novel β-amino acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, Ua, Xa, Ya, Za, R1, R2, R3